Study of BMS-986158 in Subjects With Select Advanced Cancers

Status: Active

Description

The purpose of this study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of BMS-986158 in subjects with select advanced cancers

Eligibility Criteria

Inclusion Criteria

  • Must have select advanced cancers with specific genetic profiles
  • Must have received appropriate standard of care
  • At least one measurable lesion at baseline
  • Expected to have life expectancy of at least 3 months
  • Eastern Cooperative Oncology Group (ECOG) of 0 to 1

Exclusion Criteria

  • Concomitant second malignancies
  • Uncontrolled or significant cardiovascular disease
  • Inadequate bone marrow function
  • Chronic gastrointestinal illness
  • Prior treatment with Bromodomain and Extra-Terminal (BET) inhibitor

Locations & Contacts

California

Duarte
City of Hope Comprehensive Cancer Center
Status: Active
Contact: Mihaela C. Cristea
Phone: 626-359-8111
Email: becomingapatient@coh.org

Colorado

Aurora
University of Colorado Hospital
Status: Active
Name Not Available

Missouri

Saint Louis
Siteman Cancer Center at Washington University
Status: In review
Name Not Available

Oregon

Portland
OHSU Knight Cancer Institute
Status: Active
Name Not Available

Trial Phase & Type

Trial Phase

Phase I/II

Trial Type

Treatment

Lead Organization

Lead Organization
Bristol-Myers Squibb

Trial IDs

Primary ID CA011-001
Secondary IDs NCI-2016-01458, 2015-000324-29
Clinicaltrials.gov ID NCT02419417